As Delta makes landfall, Southwest Louisiana is still without a working radar


It’s mobile radar to the rescue, and not a moment too soon.

a small clock tower in the middle of a field: The radar dome at the NWS Lake Charles sits on top of a tower that was battered by winds and is now out of commission as another hurricane heads toward it.

© NWS Lake Charles
The radar dome at the NWS Lake Charles sits on top of a tower that was battered by winds and is now out of commission as another hurricane heads toward it.

This is the story of how a moving research radar will be helping the Lake Charles, Louisiana, National Weather Service (NWS) outpost, whose radar was broken during Hurricane Laura.

The Lake Charles NWS office and radar are both located at the Lake Charles Regional Airport, which also took a significant hit during Laura.

The radar dome sits on top of an over 60-foot tower, and since wind speeds are often stronger the higher you go up, this likely led to its demise.

The problem is, the radar equipment is still not fixed, and another hurricane arrived Friday night in the the same area of Louisiana.

a person riding on the back of a truck: The SMART radar deployed to Louisiana

© Provided by CNN
The SMART radar deployed to Louisiana

Normally, when one radar site goes out, other nearby NWS offices can step in since many radar sites overlap a little.

“We have multiple radars to use, including one in Houston, Fort Polk, and Slidell,” said Roger Erickson, Warning Coordination Meteorologist for the Lake Charles NWS Office.

But those neighboring radars don’t cover the entire area, so what do you do about the gaps left behind?

“For this hurricane, we will have a portable doppler radar as well,” Erickson added.

A mobile radar, that is primarily used for research has been deployed to Louisiana to help fill in those gaps, and also provide high resolution, low-level data as well.

a young boy standing in front of a computer: Addison Alford inside the SMART radar

© Provided by CNN
Addison Alford inside the SMART radar

“In this particular case, the Shared Mobile Atmospheric Research and Teaching (SMART) Radar is here to enhance the existing

Facebook, Regeneron, Southwest: Stocks That Defined the Week


Facebook Inc.

Scrutiny of Silicon Valley is mounting in Washington. A Democratic-led House panel released a report Tuesday that said America’s biggest technology companies leveraged their dominance to stamp out competition and stifle innovation. The report capped a 16-month inquiry into the market power of Facebook, Google,




Republicans issued a separate response that didn’t endorse many of the Democrats’ policy prescriptions and accused the companies of bias against conservative viewpoints. Facebook shares fell 2.3% Tuesday.

Regeneron Pharmaceuticals Inc.

A treatment meant to jump-start President Trump’s immune response to Covid-19 provided a healthy boost to Regeneron Pharmaceuticals shares on Monday. The President touted Regeneron’s drug cocktail after doctors administered it along with other treatments, including

Gilead Sciences Inc.’s

remdesivir, which has been authorized for emergency use to treat hospitalized Covid-19 patients. The Regeneron treatment hasn’t been approved for broad use, and the company said that Mr. Trump received the drug under a compassionate-use request, which allows the use of unapproved medicines in patients with serious diseases and no other treatment options. Regeneron shares rose 7.1% Monday.

Eli Lilly

& Co.

Eli Lilly’s stock is also looking healthier after the company said it asked the FDA to authorize its Covid-19 antibody drug. The company requested U.S. authorization for emergency use of the experimental treatment for people with recently diagnosed, mild-to-moderate Covid-19. If approved, the drug could be the first to treat less severe cases of Covid-19 and open the door for a new class of coronavirus treatments capable of helping early cases and perhaps even preventing them. The drug was derived from a blood sample of one of the earliest U.S. survivors of the virus, and Eli Lilly said it could supply 100,000 doses this month and as many as one million by the end of the year